

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number  
**WO 02/092139 A1**

(51) International Patent Classification<sup>7</sup>: **A61L 2/16**, 2/18,  
A01N 33/02, 33/04, 33/16, A61K 31/13, 35/14, 35/16,  
A61M 1/36, C12N 7/06

(74) Agent: **VAN WEZENBEEK, P., M., G., F.**; P.O. Box 20,  
NL-5340 BH Oss (NL).

(21) International Application Number: PCT/EP02/05225

(81) Designated States (*national*): AE, AG, AL, AU, BA, BB,  
BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE,  
GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, LC, LK,  
LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PH,  
PL, RO, RU, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA.

(22) International Filing Date: 8 May 2002 (08.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/855,634 14 May 2001 (14.05.2001) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **AKZO  
NOBEL N.V.** [NL/NL]; Velperweg 76, NL-6824 AB Am-  
hem (NL).

Published:  
— with international search report

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **SHEPARD, Scot, R.**  
[US/US]; 1028 Swift Creek Drive, Clayton, NC (US).

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*



**WO 02/092139 A1**

(54) Title: METHODS FOR INACTIVATING VIRUSES

(57) Abstract: A method is provided for inactivating a viral or microbial agent present in a biological source material which method comprises the step of contacting the biological source material with a solution comprising an amphipathic, charged amine or amphi-  
pathic charged amine oxide.

## METHODS FOR INACTIVATING VIRUSES

## 1. TECHNICAL FIELD OF THE INVENTION

The present invention relates to methods and  
5 compositions for inactivating viruses present in samples/process  
streams of biological origin.

## 2. BACKGROUND OF THE INVENTION

It is desirable to use biological materials as sources  
for medicinal and industrial intermediates and products. Due to  
10 the very nature of the biological materials or their methods of  
production, biological materials may contain unwanted agents of  
viral origin that may be pathological or otherwise undesirable.  
The intended end-use of materials derived from biological sources  
may require a reduction in the biological activity of viral agents  
15 known to be present, or that are potentially present, in the  
source material or process additives.

Reduction of viral activity in materials is commonly  
accomplished by a number of techniques including the use of heat,  
steam, pressure, chemical treatments and other methods. However,  
20 these techniques may irreversibly alter the properties of the  
biological source material or the desired substances to be  
obtained from same. In such cases, gentle, non-denaturative and  
specific methods are required to reduce the biological activity of  
viruses without damaging the desired molecules or substances of  
25 interest.

Prior methods known in the art for inactivation of

viruses in labile process streams include photochemical treatments in the presence of Psoralens, solvent-detergent treatments (United States Patent No. 4,481,189), caprylic acid treatments (United States Patent No. 4,939,176), the use of UVC  
5 radiation (Vitex Technologies, formerly NY Blood Center), ultra short time heating (Charm Technologies, charmbio.com), photodynamic inactivation in presence of phenothiazine dyes (United States Patent No. 4,534,972), and the use of low-molecular-weight electrophilic agents that bind to nucleic acids  
10 (Vitex, Inactine product 4 patents).

### 3. SUMMARY OF THE INVENTION

The present invention relates to methods and processes of inactivating a viral contaminants in a biological  
15 source material or process intermediate. The process of the present invention involves contacting the biological source material (e.g., a host cell, cell supernatant, cell lysate, blood plasma, tissue homogenate, or other biological materials) containing a biomolecule (e.g., a recombinant or native protein,  
20 lipid, nucleic acid, or carbohydrate) of interest with a solution containing one or more alkylamine compounds. In a particular embodiment, the active ingredients are amphipathic, charged amines or amine oxides coupled to saturated hydrocarbon chains of varying lengths. In a preferred embodiment, the one  
25 or more active ingredients used are selected from the group consisting of dimethyldecylamine, dimethyltridecylamine,

dimethylundecylamine, dimethyldidecylamine,  
dimethyltetradecylamine, dimethylhexadecylamine,  
dimethyldecylamineoxide, dimethylundecylamineoxide,  
dimethyldidecylamineoxide, dimethyltetradecylamineoxide and  
5 dimethyltridecylamineoxide. These compounds may be used at  
concentrations ranging from 0.001% up to their solubility limit  
in the given solution. Preferably, the concentration of the  
active ingredients ranges from 0.005% to 5%, 0.1% to 2%, or is  
approximately 0.5% of the total solution (weight basis).

10 The pH of the solution can range from pH 2 to pH 12.  
Preferably, the solution is at a pH ranging from pH 5.0 up to pH  
8.0. More preferably, the pH ranges from pH 5.5 to 7.4, from pH  
6 to 7.4, from pH 7.0 to 7.4, or is approximately pH 7.2.

The inactivation of the viral contaminants with the  
15 active ingredient of the invention can be carried out at a  
temperature of from about 2°C to about 50°C. Preferably, the  
temperature is from about 2°C to about 30°C, 2°C to about 20°C,  
2°C to about 10°C, about 4°C, about 25°C, or at room temperature.

The biological source material may be blood plasma,  
20 other biological tissues or a recombinant source material such  
as transformed or transfected "host cells". "Host cells" are  
cells containing a biomolecule of interest. A "biomolecule of  
interest" is any biomolecule present in the biological source  
material or the host cells that one desires to isolate, purify,  
25 or formulate for subsequent processing or application. The

biological source material may be blood, blood plasma, animal tissues, plant tissues or recombinant host cells or host cell extracts. The host cells may be of any type, preferably mammalian, bacterial, yeast, fungal, plant, avian, insect, or  
5 reptilian.

#### 4. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a process for the facile and non-denaturative inactivation of viruses present or potentially present in biological source materials. The process  
10 includes contacting the source material with certain charge-modified hydrocarbons under appropriate solution conditions.

In a particular embodiment, solution conditions are adjusted by sedimentation of an insoluble source material, for example, recombinant host cells producing a recombinant protein  
15 of interest, followed by re-suspension, or by solution exchange using filtration methods, by direct modification of the existing solution conditions, or by other means of solvent exchange. Source materials suspended or co-dissolved in the appropriate solution are then contacted with certain amphipathic molecules  
20 that cause the inactivation of biological agents. Agents that may be inactivated in this way include bacteria, yeast, fungi, mycoplasma, mammalian cells, other animal cells and lipid enveloped viruses, for example, viruses of the families Flaviviridae (BVDV) Retroviridae (HIV, MuLV), Togaviridae (SFV),  
25 Rhabdoviridae (VSV), Herpesviridae (CMV).

In a preferred embodiment, a biological source

material containing a retrovirus, or suspected of containing a retrovirus, for example human immunodeficiency virus (HIV) or murine leukemia virus (MuLV) is contacted with dimethylamine and/or dimethylamine oxide compounds with alkyl chains of varying length, depending on microbe or virus type and solution conditions.

The alkyldimethylamines or alkyldimethylamine oxides do not denature individual lipid molecules or other molecules such as nucleic acids, proteins, carbohydrates, or small molecules such as organic acids, vitamins, etc. Thus, the alkyldimethylamines or alkyldimethylamine oxides are particularly suitable for the reduction of viral or microbial contaminants without the denaturation or destruction of the biomolecule of interest, such as a recombinant protein.

Once a biological source material has been obtained, it is contacted with the inactivation reagents of the present invention. The inactivation reagents comprise one or more active ingredients. In a particular embodiment, the one or more active ingredients are amphipathic, charged amines or amine oxides coupled to saturated hydrocarbon chains of varying lengths. In a preferred embodiment, the one or more active ingredients used are selected from the group consisting of dimethyldodecylamine, dimethyltridecylamine, dimethylundecylamine, dimethyldidecylamine, dimethyltetradecylamine, dimethylhexadecylamine, dimethyldecylamineoxide, dimethylundecylamineoxide, dimethyldidecylamineoxide,

dimethytetradecylamineoxide and dimethyltridecylamineoxide.

Active ingredients may be used at concentrations ranging from 0.001% up to their solubility limit. Preferably, the concentration of the detergents ranges from 0.05% to 5%, 0.1% to 2%, or is approximately 1% of the total solution.

In addition to the one or more active ingredients, in a preferred embodiment, the biological source material may also be contacted with polyols, such as glycerol, to enhance the activity of the active ingredient or to protect the molecules of interest. Preferably, the glycerol concentration is at least 0.6%, or ranges from 0.6% to 20%, 0.6% to 12%, 0.6% to 6%, 0.6% to 3%, or 0.6% to 1%.

Preferably, the solution is at a pH ranging from pH 5.0 up to pH 8.0. More preferably, the pH ranges from pH 5.5 to 7.4, from pH 6 to 7.4, from pH 7.0 to 7.4, or is approximately pH 7.2.

The microbial and/or viral inactivation can be carried out at a temperature of from about 2°C to about 50°C. Preferably, the temperature is from about 2°C to about 30°C, 2°C to about 20°C, 2°C to about 10°C, about 4°C, about 25°C, or at room temperature.

The amount of time allowed for inactivation after contacting the biological source material with the inactivation reagent may be determined by one of skill in the art. For example, the biological source material may be incubated in the

presence of the inactivation reagent for 40 minutes, 90 minutes, or 150 minutes. Shorter and longer times may also be appropriate. In general, the amount of time can be increased when the concentration of detergent is low and decreased when the amount of detergent is high. For example, an inactivation reagent with a 1% detergent concentration is effective after 40 minutes, while an inactivation reagent with a 0.1% detergent concentration should be incubated for 150 minutes or longer. For optimal inactivation, the exact amount of time necessary can be determined by a simple time-course experiment at a given concentration of active ingredient, where viability of the microbial or viral contaminant is determined over time. After a certain time point, no further decrease in viability will be observed. This time point is the optimal time necessary for inactivation.

Typically, if the biological source material is comprised of cells, the cells will lyse after contact with the inactivation reagent of the invention. After lysis of the cells, the solution can be centrifuged to collect cellular debris in the pellet, leaving the released protein or biomolecule of interest in the supernatant. The supernatant may be processed according to methods known to those of skill in the art to further isolate and purify the protein of interest. The methods utilized to further isolate and/or purify the protein of interest are highly dependent upon the characteristics and properties of the particular protein of interest, and must be



determined for each protein.

This invention is further illustrated by the following example which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference.

## 5      EXAMPLES

### 5.1    INACTIVATION OF A VIRAL CONTAMINANT IN A BIOLOGICAL SOURCE 10      MATERIAL

Chinese hamster ovary (CHO) host cells are grown to  $3 \times 10^5$  cell density and are then harvested from the reactor vessel. Cells are removed from the suspension to produce a clarified culture broth. Tetradecyldimethylamine is then added to the clarified culture broth to a concentration of 0.5% (w/w). The clarified culture broth is then incubated for a period of time during which membrane bound organisms and viruses are inactivated.

The same approach is taken for blood plasma, tissue extracts, and cell extracts. The amount of detergent, time of incubation, temperature of incubation, and other parameters are readily ascertained by those skilled in the art. Appropriate solution conditions and incubation times are identified and validated by the intentional addition, or "spike", of microbes or viruses of known titer into the biological source material prior to the addition of the charge-modified hydrocarbon. The

charge-modified hydrocarbon is then added to the biological source material and samples are withdrawn at specific time points. The samples are then analyzed by appropriate methods, known to those skilled in the art, that measure the biological activity, growth characteristics, or infectivity of the microbe or virus initially "spiked" into the biological source material.

WHAT IS CLAIMED IS:

1. A method of inactivating a viral or microbial agent present in a biological source material, comprising the step of  
5 contacting the biological source material with a solution comprising an effective amount of an active ingredient, wherein the active ingredient is an amphipathic charged amine or an amphipathic charged amine oxide.
2. A method of inactivating a viral or microbial agent in  
10 a biological source material comprising the step of contacting the biological source material with a solution comprising an effective amount of an active ingredient, wherein the active ingredient is selected from the group consisting of:  
dimethyldecylamine, dimethyltridecylamine, dimethylundecylamine,  
15 dimethyldidecylamine, dimethyltetradecylamine, dimethylhexadecylamine, dimethyldecylamineoxide, dimethylundecylamineoxide, dimethyldidecylamineoxide, dimethyltetradecylamineoxide and dimethyltridecylamineoxide.
3. The method of claim 3, wherein the solution further  
20 comprises glycerol.
4. The method of claim 4, wherein the active ingredient comprises between 0.001 to 10 percent of the solution.
5. The method of claim 4, wherein the glycerol comprises between 0.6 to 6 percent of the solution.
- 25 6. The method of claim 5, wherein the glycerol comprises between 0.6 to 6 percent of the solution.

7. The method of claim 2, wherein the active ingredient is dimethyltetradecylamine.

8. The method of claim 1, wherein the agent is a member of the group consisting of:

5           bacteria, yeast, fungi, mycoplasma, mammalian cells, other animal cells, viruses, or lipid enveloped viruses such as, Flaviviridae, Retroviridae, Togaviridae, Rhabdoviridae, Herpesviridae, VSV, SFV, HIV, MuLV, BVDV, and CMV.

10          9. The method of claim 2, wherein the agent is a member of the group consisting of:

            bacteria, yeast, fungi, mycoplasma, mammalian cells, other animal cells, viruses, or lipid enveloped viruses such as, Flaviviridae, Retroviridae, Togaviridae, Rhabdoviridae, Herpesviridae, VSV, SFV, HIV, MuLV, BVDV, and CMV.

15

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/05225

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L2/16 A61L2/18 A01N33/02 A01N33/04 A01N33/16  
A61K31/13 A61K35/14 A61K35/16 A61M1/36 C12N7/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L A01N A61K A61M C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 614 405 A (EIBL JOHANN ET AL) 25 March 1997 (1997-03-25) column 4, line 59 -column 5, line 13; example 3	1,2,4, 7-9
Y	---	3,5,6
Y	US 5 186 945 A (SHANBROM EDWARD) 16 February 1993 (1993-02-16) column 8, line 50 - line 60 column 14, line 65 -column 15, line 8; claim 21	3,5,6
X	WO 92 16201 A (MICHAELS E B RES ASS) 1 October 1992 (1992-10-01) page 9, line 9 - line 33; examples 5-7 --- -/--	1,2,7-9

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 July 2002

Date of mailing of the international search report

01/08/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Edmüller, P

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/05225

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 02028 A (HEMASURE INC) 23 January 1997 (1997-01-23) page 9, line 5 -page 12, line 22; claims 1-19 ----	1-9
A	WO 97 07674 A (PENTOSE PHARMACEUTICALS INC ;BUDOWSKY EDWARD I (US)) 6 March 1997 (1997-03-06) claims 1-19 ----	1-9
A	WO 98 42373 A (GREALLY DECLAN ;LAWRENCE MICHELLE IRENE GREGAR (GB); MEDEVA EUROP) 1 October 1998 (1998-10-01) page 3, line 3 -page 6, line 6 -----	1-9

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/05225

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5614405	A	25-03-1997	AT 402891 B	25-09-1997
			AT 123791 A	15-02-1997
			AT 183396 T	15-09-1999
			AU 648414 B2	21-04-1994
			AU 1830692 A	24-12-1992
			CA 2071567 A1	21-12-1992
			CZ 285115 B6	12-05-1999
			CZ 285552 B6	15-09-1999
			DE 59209735 D1	23-09-1999
			DK 519901 T3	14-02-2000
			EP 0519901 A2	23-12-1992
			EP 0882455 A1	09-12-1998
			ES 2137178 T3	16-12-1999
			FI 922850 A , B,	21-12-1992
			FI 962613 A	24-06-1996
			HU 213470 B	30-06-1997
			HU 9500458 A3	28-12-1995
			JP 3011819 B2	21-02-2000
			JP 5186358 A	27-07-1993
			JP 2000080042 A	21-03-2000
			NO 922420 A	21-12-1992
			NO 973996 A	21-12-1992
			SK 190292 A3	10-05-1995
			US 5864016 A	26-01-1999
US 5186945	A	16-02-1993	AU 4525089 A	12-06-1990
			AU 4525289 A	12-06-1990
			AU 4636589 A	12-06-1990
			AU 4653989 A	12-06-1990
			AU 4664989 A	12-06-1990
			AU 4750390 A	12-06-1990
			EP 0399027 A1	28-11-1990
			EP 0406369 A1	09-01-1991
			JP 3503287 T	25-07-1991
			JP 3503170 T	18-07-1991
			WO 9005550 A1	31-05-1990
			WO 9005520 A2	31-05-1990
			WO 9005533 A1	31-05-1990
			WO 9005546 A1	31-05-1990
			WO 9005547 A1	31-05-1990
			WO 9005548 A1	31-05-1990
			US 4891221 A	02-01-1990
			US 4933169 A	12-06-1990
			US 5156973 A	20-10-1992
			US 5128149 A	07-07-1992
			US 5128150 A	07-07-1992
			US 5019495 A	28-05-1991
			US 5204324 A	20-04-1993
WO 9216201	A	01-10-1992	US 5314917 A	24-05-1994
			AT 176399 T	15-02-1999
			AT 201593 T	15-06-2001
			AU 661968 B2	17-08-1995
			AU 8222791 A	21-10-1992
			CA 2106683 A1	23-09-1992
			DE 69130871 D1	18-03-1999
			DE 69130871 T2	23-09-1999
			DE 69132621 D1	05-07-2001

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/05225

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9216201	A		DE 69132621 T2	18-04-2002
			EP 0576425 A1	05-01-1994
			EP 0733361 A2	25-09-1996
			JP 3228928 B2	12-11-2001
			JP 6505700 T	30-06-1994
			JP 2002037733 A	06-02-2002
			KR 221486 B1	15-09-1999
			KR 227773 B1	15-03-2000
			OA 9911 A	15-09-1994
			RU 2110256 C1	10-05-1998
			WO 9216201 A1	01-10-1992
			US 5389676 A	14-02-1995
			US 6297278 B1	02-10-2001
WO 9702028	A	23-01-1997	AU 7717396 A	05-02-1997
			BR 9606454 A	30-09-1997
			CA 2198085 A1	23-01-1997
			EP 0792146 A1	03-09-1997
			JP 10506927 T	07-07-1998
			WO 9702028 A1	23-01-1997
WO 9707674	A	06-03-1997	US 6114108 A	05-09-2000
			AT 217144 T	15-05-2002
			AU 694892 B2	30-07-1998
			AU 6909996 A	19-03-1997
			BR 9610306 A	06-07-1999
			CA 2230671 A1	06-03-1997
			DE 69621161 D1	13-06-2002
			EP 1129728 A1	05-09-2001
			EP 0915648 A1	19-05-1999
			JP 2001520635 T	30-10-2001
			NO 980881 A	27-04-1998
			NZ 316787 A	29-11-1999
			PL 325338 A1	20-07-1998
			WO 9707674 A1	06-03-1997
			US 6136586 A	24-10-2000
			US 2002034724 A1	21-03-2002
WO 9842373	A	01-10-1998	EP 0981370 A1	01-03-2000
			WO 9842373 A1	01-10-1998
			GB 2323279 A ,B	23-09-1998
			US 6403363 B1	11-06-2002